Indication name: Pemphigus
Vulgaris
Pemphigus vulgaris is an autoimmune
blistering disease. The keratinocytes are cemented together at unique sticky
spots called desmosomes. In pemphigus vulgaris, immunoglobulin type G (IgG)
autoantibodies bind to a protein called desmoglein 3 (dsg3), which is found in
desmosomes in the keratinocytes near the bottom of the epidermis. The result is
the keratinocytes separate from each other, and are replaced by fluid in the
form of blisters.
Thelansis Epidemiology study
indicates It has a prevalence of around 30,000 cases in the USA and an
incidence of 1–10 new cases per 1 million people
Competitive landscape of PV
includes country specific approved as well as pipeline therapies. Any asset/
product specific designation or review and Accelerated Approval are being
tracked and supplemented with analyst commentary.
KOLs
insights of PV across 8 MM market from center of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm
and Unmet needs.
PV Market Forecast: Patient Based
Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with
sourcing , Market Event and Product Event , Country specific Forecast Model,
Market uptake and patient share uptake , Attribute Analysis , Analog Analysis ,
Disease burden and pricing scenario, Summary and Insights.
S. No Asset Company Stage
1 Mycophenolate Mofetil Hoffmann-La Roche Phase 3
2 PRN1008 Principia Biopharma Australia Pty
Ltd. Phase 3
3 DSG3-CAART Cabaletta Bio Phase 1
4 Efgartigimod PH20 SC argenx Phase 3
No comments:
Post a Comment